MoonLake Immunotherapeutics
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$244.8M | -$143.1M | -$54.1M | -$65.1M | -$4.6M |
| Operating expenses | $244.8M | $143.1M | $54.1M | $65.1M | — |
| Cash from operations | -$196.0M | -$116.6M | -$42.8M | -$55.9M | -$611,071 |
| Capital expenditure | $35,000 | $520,000 | $284,000 | $16,009 | — |
| Free cash flow | -$196.0M | -$117.1M | -$43.1M | -$55.9M | — |
| Share repurchases | — | $50 | $0 | $0 | — |
| Impairments | $0 | $0 | $0 | — | — |
| Total assets | $424.4M | $477.9M | $526.5M | $76.8M | $9.7M |
| Total liabilities | $120.0M | $24.5M | $13.0M | $8.1M | $21.3M |
Shares outstanding 73.6M · Free float 82.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.